NO317059B1 - Nye vitamin D-derivater med C-25-substituenter, fremgangsmate for fremstilling av disse, mellomprodukter og anvendelse av vitamin D-derivatene ved fremstilling av legemidler - Google Patents

Nye vitamin D-derivater med C-25-substituenter, fremgangsmate for fremstilling av disse, mellomprodukter og anvendelse av vitamin D-derivatene ved fremstilling av legemidler Download PDF

Info

Publication number: NO317059B1
Authority: NO; Norway
Prior art keywords: secocholesta; cyclo; triol; tetraene; methyl
Prior art date: 1995-06-14

Application number

NO19975852A

Other languages

English (en)

Norwegian (no)

Other versions

NO975852D0 (no

NO975852L (no

Inventor

Andreas Steinmeyer

Gerald Kirsch

Guenter Neef

Katica Schwarz

Herbert Wiesinger

Ruth Thieroff-Ekerdt

Andreas Menrad

Martin Heberey

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-14

Filing date

1997-12-12

Publication date

2004-08-02

1997-12-12 Application filed by Schering Ag filed Critical Schering Ag

1997-12-12 Publication of NO975852D0 publication Critical patent/NO975852D0/no

1998-02-16 Publication of NO975852L publication Critical patent/NO975852L/no

2004-08-02 Publication of NO317059B1 publication Critical patent/NO317059B1/no

Links

238000000034 method Methods 0.000 title claims abstract description 11
150000003710 vitamin D derivatives Chemical class 0.000 title claims description 16
239000003814 drug Substances 0.000 title claims description 7
229940079593 drug Drugs 0.000 title claims 2
238000002360 preparation method Methods 0.000 title description 9
239000000543 intermediate Substances 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims abstract description 104
-1 hydroxy- Chemical class 0.000 claims description 50
239000011612 calcitriol Substances 0.000 claims description 33
229960005084 calcitriol Drugs 0.000 claims description 33
235000020964 calcitriol Nutrition 0.000 claims description 31
125000004432 carbon atom Chemical group C* 0.000 claims description 30
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 29
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 29
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
125000006239 protecting group Chemical group 0.000 claims description 26
238000006243 chemical reaction Methods 0.000 claims description 23
239000000460 chlorine Substances 0.000 claims description 15
238000003786 synthesis reaction Methods 0.000 claims description 14
230000015572 biosynthetic process Effects 0.000 claims description 13
238000002560 therapeutic procedure Methods 0.000 claims description 13
208000037147 Hypercalcaemia Diseases 0.000 claims description 11
230000000148 hypercalcaemia Effects 0.000 claims description 11
125000000217 alkyl group Chemical group 0.000 claims description 10
229910052799 carbon Inorganic materials 0.000 claims description 10
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
201000010099 disease Diseases 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
229920006395 saturated elastomer Polymers 0.000 claims description 9
125000001424 substituent group Chemical group 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 8
125000002252 acyl group Chemical group 0.000 claims description 7
208000030915 hypercalcemia disease Diseases 0.000 claims description 7
125000000468 ketone group Chemical group 0.000 claims description 7
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 7
206010028980 Neoplasm Diseases 0.000 claims description 5
208000001132 Osteoporosis Diseases 0.000 claims description 5
125000003435 aroyl group Chemical group 0.000 claims description 5
125000004122 cyclic group Chemical group 0.000 claims description 5
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 5
229930195734 saturated hydrocarbon Natural products 0.000 claims description 5
125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 5
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 4
206010018691 Granuloma Diseases 0.000 claims description 4
229910052801 chlorine Inorganic materials 0.000 claims description 4
230000032050 esterification Effects 0.000 claims description 4
238000005886 esterification reaction Methods 0.000 claims description 4
230000035558 fertility Effects 0.000 claims description 4
229910052731 fluorine Inorganic materials 0.000 claims description 4
125000001153 fluoro group Chemical group F* 0.000 claims description 4
230000036961 partial effect Effects 0.000 claims description 4
238000011321 prophylaxis Methods 0.000 claims description 4
102000003982 Parathyroid hormone Human genes 0.000 claims description 3
108090000445 Parathyroid hormone Proteins 0.000 claims description 3
206010039984 Senile osteoporosis Diseases 0.000 claims description 3
206010040799 Skin atrophy Diseases 0.000 claims description 3
125000004423 acyloxy group Chemical group 0.000 claims description 3
125000002837 carbocyclic group Chemical group 0.000 claims description 3
206010012601 diabetes mellitus Diseases 0.000 claims description 3
208000032839 leukemia Diseases 0.000 claims description 3
239000000199 parathyroid hormone Substances 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
208000001685 postmenopausal osteoporosis Diseases 0.000 claims description 3
201000000306 sarcoidosis Diseases 0.000 claims description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
208000030507 AIDS Diseases 0.000 claims description 2
208000002874 Acne Vulgaris Diseases 0.000 claims description 2
206010003210 Arteriosclerosis Diseases 0.000 claims description 2
208000023275 Autoimmune disease Diseases 0.000 claims description 2
208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims description 2
206010009900 Colitis ulcerative Diseases 0.000 claims description 2
208000011231 Crohn disease Diseases 0.000 claims description 2
201000002980 Hyperparathyroidism Diseases 0.000 claims description 2
208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
206010027476 Metastases Diseases 0.000 claims description 2
206010060862 Prostate cancer Diseases 0.000 claims description 2
201000004681 Psoriasis Diseases 0.000 claims description 2
208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims description 2
206010042971 T-cell lymphoma Diseases 0.000 claims description 2
201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
206010000496 acne Diseases 0.000 claims description 2
230000000735 allogeneic effect Effects 0.000 claims description 2
125000005333 aroyloxy group Chemical group 0.000 claims description 2
208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
201000008275 breast carcinoma Diseases 0.000 claims description 2
FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical group CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 claims description 2
230000003463 hyperproliferative effect Effects 0.000 claims description 2
206010020917 hypervitaminosis D Diseases 0.000 claims description 2
206010021198 ichthyosis Diseases 0.000 claims description 2
239000003022 immunostimulating agent Substances 0.000 claims description 2
239000013067 intermediate product Substances 0.000 claims description 2
201000009019 intestinal benign neoplasm Diseases 0.000 claims description 2
208000037841 lung tumor Diseases 0.000 claims description 2
206010025135 lupus erythematosus Diseases 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
206010028417 myasthenia gravis Diseases 0.000 claims description 2
230000000010 osteolytic effect Effects 0.000 claims description 2
231100000572 poisoning Toxicity 0.000 claims description 2
230000000607 poisoning effect Effects 0.000 claims description 2
108090000765 processed proteins & peptides Proteins 0.000 claims description 2
201000001514 prostate carcinoma Diseases 0.000 claims description 2
201000006409 renal osteodystrophy Diseases 0.000 claims description 2
208000017520 skin disease Diseases 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
201000008827 tuberculosis Diseases 0.000 claims description 2
229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 2
230000029663 wound healing Effects 0.000 claims description 2
125000001183 hydrocarbyl group Chemical group 0.000 claims 2
208000024827 Alzheimer disease Diseases 0.000 claims 1
206010058314 Dysplasia Diseases 0.000 claims 1
208000012659 Joint disease Diseases 0.000 claims 1
208000001126 Keratosis Diseases 0.000 claims 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
210000003169 central nervous system Anatomy 0.000 claims 1
229960001438 immunostimulant agent Drugs 0.000 claims 1
230000003308 immunostimulating effect Effects 0.000 claims 1
208000015122 neurodegenerative disease Diseases 0.000 claims 1
230000002093 peripheral effect Effects 0.000 claims 1
210000001428 peripheral nervous system Anatomy 0.000 claims 1
201000003068 rheumatic fever Diseases 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 303
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 234
238000005160 1H NMR spectroscopy Methods 0.000 description 87
239000006260 foam Substances 0.000 description 86
235000019439 ethyl acetate Nutrition 0.000 description 78
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 71
239000000741 silica gel Substances 0.000 description 70
229910002027 silica gel Inorganic materials 0.000 description 70
239000000243 solution Substances 0.000 description 64
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 63
239000000203 mixture Substances 0.000 description 62
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 57
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 55
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 44
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 37
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
229910052938 sodium sulfate Inorganic materials 0.000 description 29
235000011152 sodium sulphate Nutrition 0.000 description 29
239000011780 sodium chloride Substances 0.000 description 28
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 26
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 26
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 25
229910052786 argon Inorganic materials 0.000 description 22
238000004587 chromatography analysis Methods 0.000 description 22
YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 22
239000012074 organic phase Substances 0.000 description 22
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
210000004027 cell Anatomy 0.000 description 21
239000002904 solvent Substances 0.000 description 17
239000002244 precipitate Substances 0.000 description 16
238000012360 testing method Methods 0.000 description 16
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
238000000926 separation method Methods 0.000 description 15
239000012230 colorless oil Substances 0.000 description 14
150000001299 aldehydes Chemical class 0.000 description 13
UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 12
239000012071 phase Substances 0.000 description 12
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 11
230000000694 effects Effects 0.000 description 11
238000004128 high performance liquid chromatography Methods 0.000 description 11
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 10
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
102000009310 vitamin D receptors Human genes 0.000 description 9
108050000156 vitamin D receptors Proteins 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 8
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
150000001298 alcohols Chemical class 0.000 description 7
239000011575 calcium Substances 0.000 description 7
229910052791 calcium Inorganic materials 0.000 description 7
AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 7
DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 7
239000003921 oil Substances 0.000 description 7
229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
235000017557 sodium bicarbonate Nutrition 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
229930003316 Vitamin D Natural products 0.000 description 6
230000009471 action Effects 0.000 description 6
MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 6
238000001035 drying Methods 0.000 description 6
238000000605 extraction Methods 0.000 description 6
230000003779 hair growth Effects 0.000 description 6
229910052744 lithium Inorganic materials 0.000 description 6
AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 6
238000011282 treatment Methods 0.000 description 6
235000019166 vitamin D Nutrition 0.000 description 6
239000011710 vitamin D Substances 0.000 description 6
239000011647 vitamin D3 Substances 0.000 description 6
229940046008 vitamin d Drugs 0.000 description 6
229940021056 vitamin d3 Drugs 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
230000002378 acidificating effect Effects 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
150000002900 organolithium compounds Chemical class 0.000 description 5
210000003491 skin Anatomy 0.000 description 5
239000012279 sodium borohydride Substances 0.000 description 5
229910000033 sodium borohydride Inorganic materials 0.000 description 5
239000007787 solid Substances 0.000 description 5
VEPTXBCIDSFGBF-UHFFFAOYSA-M tetrabutylazanium;fluoride;trihydrate Chemical compound O.O.O.[F-].CCCC[N+](CCCC)(CCCC)CCCC VEPTXBCIDSFGBF-UHFFFAOYSA-M 0.000 description 5
GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 4
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
239000002585 base Substances 0.000 description 4
239000006285 cell suspension Substances 0.000 description 4
239000012043 crude product Substances 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 4
239000007800 oxidant agent Substances 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
229910000104 sodium hydride Inorganic materials 0.000 description 4
239000007858 starting material Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
235000005282 vitamin D3 Nutrition 0.000 description 4
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
238000010626 work up procedure Methods 0.000 description 4
ANOOTOPTCJRUPK-UHFFFAOYSA-N 1-iodohexane Chemical compound CCCCCCI ANOOTOPTCJRUPK-UHFFFAOYSA-N 0.000 description 3
BLXSFCHWMBESKV-UHFFFAOYSA-N 1-iodopentane Chemical compound CCCCCI BLXSFCHWMBESKV-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000001668 calcitriol derivatives Chemical class 0.000 description 3
239000003638 chemical reducing agent Substances 0.000 description 3
NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 3
229940043279 diisopropylamine Drugs 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
239000012634 fragment Substances 0.000 description 3
210000003780 hair follicle Anatomy 0.000 description 3
150000002430 hydrocarbons Chemical group 0.000 description 3
230000000121 hypercalcemic effect Effects 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 3
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 3
ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
239000003104 tissue culture media Substances 0.000 description 3
239000000052 vinegar Substances 0.000 description 3
235000021419 vinegar Nutrition 0.000 description 3
238000005406 washing Methods 0.000 description 3
VZAWCLCJGSBATP-UHFFFAOYSA-N 1-cycloundecyl-1,2-diazacycloundecane Chemical compound C1CCCCCCCCCC1N1NCCCCCCCCC1 VZAWCLCJGSBATP-UHFFFAOYSA-N 0.000 description 2
LMHCYRULPLGEEZ-UHFFFAOYSA-N 1-iodoheptane Chemical compound CCCCCCCI LMHCYRULPLGEEZ-UHFFFAOYSA-N 0.000 description 2
IBXNCJKFFQIKKY-UHFFFAOYSA-N 1-pentyne Chemical compound CCCC#C IBXNCJKFFQIKKY-UHFFFAOYSA-N 0.000 description 2
ZMZGFLUUZLELNE-UHFFFAOYSA-N 2,3,5-triiodobenzoic acid Chemical compound OC(=O)C1=CC(I)=CC(I)=C1I ZMZGFLUUZLELNE-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
201000004384 Alopecia Diseases 0.000 description 2
229910004664 Cerium(III) chloride Inorganic materials 0.000 description 2
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
229910010084 LiAlH4 Inorganic materials 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
JWIPGAFCGUDKEY-UHFFFAOYSA-L O[Cr](Cl)(=O)=O.C1=CC=NC=C1 Chemical compound O[Cr](Cl)(=O)=O.C1=CC=NC=C1 JWIPGAFCGUDKEY-UHFFFAOYSA-L 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
238000009835 boiling Methods 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000011097 chromatography purification Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000002950 deficient Effects 0.000 description 2
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000000668 effect on calcium Effects 0.000 description 2
230000002900 effect on cell Effects 0.000 description 2
210000002615 epidermis Anatomy 0.000 description 2
125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
238000005805 hydroxylation reaction Methods 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000002510 keratinocyte Anatomy 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
229910052753 mercury Inorganic materials 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
JXBAKCMWFYJKGF-UHFFFAOYSA-N methyl 1-acetylcyclopropane-1-carboxylate Chemical compound COC(=O)C1(C(C)=O)CC1 JXBAKCMWFYJKGF-UHFFFAOYSA-N 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
239000002674 ointment Substances 0.000 description 2
AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 2
229960003531 phenolsulfonphthalein Drugs 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000000047 product Substances 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000005297 pyrex Substances 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
LOVRVVSIBIVFTN-VSGBNLITSA-N tert-butyl-[(1r,3r)-3-[tert-butyl(dimethyl)silyl]oxy-5-(2-diphenylphosphorylethylidene)cyclohexyl]oxy-dimethylsilane Chemical compound C1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@H](O[Si](C)(C)C(C)(C)C)CC1=CCP(=O)(C=1C=CC=CC=1)C1=CC=CC=C1 LOVRVVSIBIVFTN-VSGBNLITSA-N 0.000 description 2
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
150000003703 vitamin D2 derivatives Chemical class 0.000 description 2
KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
BKPFTDPOCSONMX-SNAWJCMRSA-N (e)-1-iodopent-1-ene Chemical compound CCC\C=C\I BKPFTDPOCSONMX-SNAWJCMRSA-N 0.000 description 1
IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 1
BULLJMKUVKYZDJ-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-6-iodohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)I BULLJMKUVKYZDJ-UHFFFAOYSA-N 0.000 description 1
PGRFXXCKHGIFSV-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4-nonafluoro-4-iodobutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)I PGRFXXCKHGIFSV-UHFFFAOYSA-N 0.000 description 1
HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
UALIMNAGTUSPFS-UHFFFAOYSA-N 1-(2-methyl-1,3-dioxolan-2-yl)cyclopropane-1-carbaldehyde Chemical compound C1CC1(C=O)C1(C)OCCO1 UALIMNAGTUSPFS-UHFFFAOYSA-N 0.000 description 1
YRTFLDFDKPFNCJ-UHFFFAOYSA-N 1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-2-oxo-4-[3-(3-pyrrolidin-1-ylpropoxy)phenyl]-1,8-naphthyridin-3-yl]urea;dihydrochloride Chemical compound Cl.Cl.CC(C)C=1C=C(N)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C(C=1)=CC=CC=1OCCCN1CCCC1 YRTFLDFDKPFNCJ-UHFFFAOYSA-N 0.000 description 1
MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 1
YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical compound CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 description 1
CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
RHPYJNBYNQILFP-UHFFFAOYSA-N 1-dimethoxyphosphorylhexan-2-one Chemical compound CCCCC(=O)CP(=O)(OC)OC RHPYJNBYNQILFP-UHFFFAOYSA-N 0.000 description 1
UWLHSHAHTBJTBA-UHFFFAOYSA-N 1-iodooctane Chemical compound CCCCCCCCI UWLHSHAHTBJTBA-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
IOBKAWMJICSVBL-UHFFFAOYSA-N 3-ethoxycarbonylpentan-3-ylphosphonic acid Chemical compound CCOC(=O)C(CC)(CC)P(O)(O)=O IOBKAWMJICSVBL-UHFFFAOYSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
206010001766 Alopecia totalis Diseases 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
102100023995 Beta-nerve growth factor Human genes 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
206010068975 Bone atrophy Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 1
241000700198 Cavia Species 0.000 description 1
206010008263 Cervical dysplasia Diseases 0.000 description 1
LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
208000005422 Foreign-Body reaction Diseases 0.000 description 1
206010020112 Hirsutism Diseases 0.000 description 1
238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
108010081689 Osteopontin Proteins 0.000 description 1
102000004264 Osteopontin Human genes 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
230000018199 S phase Effects 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
241000282887 Suidae Species 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
KUXYVHJHQMKRTQ-UHFFFAOYSA-N [1-(2-methyl-1,3-dioxolan-2-yl)cyclopropyl]methanol Chemical compound C1CC1(CO)C1(C)OCCO1 KUXYVHJHQMKRTQ-UHFFFAOYSA-N 0.000 description 1
YFXWODPYUNGUEE-UHFFFAOYSA-N [I].[Li] Chemical group [I].[Li] YFXWODPYUNGUEE-UHFFFAOYSA-N 0.000 description 1
WXZIKFXSSPSWSR-UHFFFAOYSA-N [Li]CCCCC Chemical compound [Li]CCCCC WXZIKFXSSPSWSR-UHFFFAOYSA-N 0.000 description 1
ILOYPIODPORGAZ-UHFFFAOYSA-N [Li]CCCCCCC Chemical compound [Li]CCCCCCC ILOYPIODPORGAZ-UHFFFAOYSA-N 0.000 description 1
CPNOVDWZRIYWQV-UHFFFAOYSA-N [Li]CCCCCCCC Chemical compound [Li]CCCCCCCC CPNOVDWZRIYWQV-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
208000009621 actinic keratosis Diseases 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
125000006241 alcohol protecting group Chemical group 0.000 description 1
238000005575 aldol reaction Methods 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
206010068168 androgenetic alopecia Diseases 0.000 description 1
201000002996 androgenic alopecia Diseases 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000008416 bone turnover Effects 0.000 description 1
150000001649 bromium compounds Chemical class 0.000 description 1
LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 1
244000309464 bull Species 0.000 description 1
208000019748 bullous skin disease Diseases 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000002308 calcification Effects 0.000 description 1
230000003913 calcium metabolism Effects 0.000 description 1
230000003185 calcium uptake Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
208000022605 chemotherapy-induced alopecia Diseases 0.000 description 1
KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical class Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000001609 comparable effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
GUDMZGLFZNLYEY-UHFFFAOYSA-N cyclopropylmethanol Chemical compound OCC1CC1 GUDMZGLFZNLYEY-UHFFFAOYSA-N 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
JGHYBJVUQGTEEB-UHFFFAOYSA-M dimethylalumanylium;chloride Chemical compound C[Al](C)Cl JGHYBJVUQGTEEB-UHFFFAOYSA-M 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000001339 epidermal cell Anatomy 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000007306 functionalization reaction Methods 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
230000031774 hair cycle Effects 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
238000012750 in vivo screening Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000006317 isomerization reaction Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
150000002642 lithium compounds Chemical class 0.000 description 1
KCTBOHUTRYYLJA-UHFFFAOYSA-N lithium;2h-furan-2-ide Chemical compound [Li+].C=1C=[C-]OC=1 KCTBOHUTRYYLJA-UHFFFAOYSA-N 0.000 description 1
YSQFBLFEYNOIBW-UHFFFAOYSA-N lithium;cyclopropane Chemical compound [Li+].C1C[CH-]1 YSQFBLFEYNOIBW-UHFFFAOYSA-N 0.000 description 1
CETVQRFGPOGIQJ-UHFFFAOYSA-N lithium;hexane Chemical compound [Li+].CCCCC[CH2-] CETVQRFGPOGIQJ-UHFFFAOYSA-N 0.000 description 1
XBEREOHJDYAKDA-UHFFFAOYSA-N lithium;propane Chemical compound [Li+].CC[CH2-] XBEREOHJDYAKDA-UHFFFAOYSA-N 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000006263 metalation reaction Methods 0.000 description 1
GXTOYOQSOMLOOK-UHFFFAOYSA-N methyl 1-(2-methyl-1,3-dioxolan-2-yl)cyclopropane-1-carboxylate Chemical compound O1CCOC1(C)C1(C(=O)OC)CC1 GXTOYOQSOMLOOK-UHFFFAOYSA-N 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
PHVXTQIROLEEDB-UHFFFAOYSA-N n-[2-(2-chlorophenyl)ethyl]-4-[[3-(2-methylphenyl)piperidin-1-yl]methyl]-n-pyrrolidin-3-ylbenzamide Chemical compound CC1=CC=CC=C1C1CN(CC=2C=CC(=CC=2)C(=O)N(CCC=2C(=CC=CC=2)Cl)C2CNCC2)CCC1 PHVXTQIROLEEDB-UHFFFAOYSA-N 0.000 description 1
PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000011164 ossification Effects 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
230000001009 osteoporotic effect Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
230000037361 pathway Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
125000005003 perfluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 description 1
125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
125000005005 perfluorohexyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 description 1
125000005008 perfluoropentyl group Chemical group FC(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)* 0.000 description 1
125000005009 perfluoropropyl group Chemical group FC(C(C(F)(F)F)(F)F)(F)* 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000008063 pharmaceutical solvent Substances 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000001472 potassium tartrate Substances 0.000 description 1
229940111695 potassium tartrate Drugs 0.000 description 1
235000011005 potassium tartrates Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000012746 preparative thin layer chromatography Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
210000004765 promyelocyte Anatomy 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
210000005000 reproductive tract Anatomy 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
208000007442 rickets Diseases 0.000 description 1
TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 description 1
229910052707 ruthenium Inorganic materials 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
231100000489 sensitizer Toxicity 0.000 description 1
125000003808 silyl group Chemical class [H][Si]([H])([H])[*] 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229940082054 sodium bicarbonate / sodium chloride Drugs 0.000 description 1
WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
239000001433 sodium tartrate Substances 0.000 description 1
229960002167 sodium tartrate Drugs 0.000 description 1
235000011004 sodium tartrates Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
239000003826 tablet Substances 0.000 description 1
MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 1
150000004684 trihydrates Chemical class 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Hematology (AREA)
Oncology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Nutrition Science (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO19975852A 1995-06-14 1997-12-12 Nye vitamin D-derivater med C-25-substituenter, fremgangsmate for fremstilling av disse, mellomprodukter og anvendelse av vitamin D-derivatene ved fremstilling av legemidler NO317059B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19522797		1995-06-14
PCT/EP1996/001788 WO1997000242A1 (de)	1995-06-14	1996-04-30	Neue vitamin d-derivate mit substituenten an c-25, verfahren zu ihrer herstellung, zwischenprodukte und die verwendung zur herstellung von arzneimitteln

Publications (3)

Publication Number	Publication Date
NO975852D0 NO975852D0 (no)	1997-12-12
NO975852L NO975852L (no)	1998-02-16
NO317059B1 true NO317059B1 (no)	2004-08-02

Family

ID=7765061

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19975852A NO317059B1 (no)	1995-06-14	1997-12-12	Nye vitamin D-derivater med C-25-substituenter, fremgangsmate for fremstilling av disse, mellomprodukter og anvendelse av vitamin D-derivatene ved fremstilling av legemidler

Country Status (19)

Country	Link
US (2)	US6372731B1 (cs)
EP (1)	EP0832063B1 (cs)
JP (1)	JPH11507649A (cs)
AT (1)	ATE189888T1 (cs)
AU (1)	AU707942B2 (cs)
CA (1)	CA2224440A1 (cs)
CZ (1)	CZ291915B6 (cs)
DE (1)	DE59604498D1 (cs)
DK (1)	DK0832063T3 (cs)
ES (1)	ES2144239T3 (cs)
GR (1)	GR3033459T3 (cs)
HU (1)	HUP9801059A3 (cs)
IL (1)	IL118366A (cs)
NO (1)	NO317059B1 (cs)
NZ (1)	NZ307549A (cs)
PT (1)	PT832063E (cs)
TW (1)	TW351714B (cs)
WO (1)	WO1997000242A1 (cs)
ZA (1)	ZA965098B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5795882A (en) *	1992-06-22	1998-08-18	Bone Care International, Inc.	Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
DE19619036A1 (de)	1996-04-30	1997-11-13	Schering Ag	Neue Vitamin D-Derivate mit carbo- oder heterocyclischen Substituenten an C-25, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
US6392071B1 (en) *	1997-03-17	2002-05-21	Wisconsin Alumni: Research Foundation	26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
WO1999012894A1 (en) *	1997-09-08	1999-03-18	F. Hoffmann-La Roche Ag	1,3-dihydroxy-20,20-dialkyl-vitamin d3 analogs
DE19744127B4 (de) *	1997-10-01	2006-10-05	Schering Ag	Neue Vitamin D-Derivate mit Cyclopropylringen in den Seitenketten, Verfahren und Zwischenprodukte zu ihrer Herstellung sowie ihre Verwendung zur Herstellung von Arzneimitteln
US6531459B1 (en) *	1997-12-17	2003-03-11	Schering Aktiengesellschaft	Vitamin D derivatives with phosphorus atoms in the side chains
EP0927721A1 (de) *	1997-12-17	1999-07-07	Schering Aktiengesellschaft	Neue Vitamin D-Derivate mit Phosphoratomen in den Seitenketten, Zwischenprodukte bei ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
US5972917A (en) *	1998-05-29	1999-10-26	Bone Care Int Inc	1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
US20040019024A1 (en) *	2000-08-23	2004-01-29	Seiichi Ishizuka	Use of vitamin d derivatives as bone resorption inhibitors
US7491711B2 (en) *	2001-09-21	2009-02-17	Roche Palo Alto Llc	Methods of treatment using 3-desoxy vitamin D3 analogs
DE10156596A1 (de) *	2001-11-13	2003-05-28	Schering Ag	Vitamin D-Derivate mit Acyloxygruppen in der Seitenkette, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
US7351869B2 (en) *	2002-11-18	2008-04-01	Teva Pharmaceutical Industries Ltd	Crystallization method for purification of calcipotriene
US7915242B2 (en) *	2004-02-17	2011-03-29	Wisconsin Alumni Research Foundation	Vitamin D receptor antagonists and their use in treating asthma
US7094775B2 (en)	2004-06-30	2006-08-22	Bone Care International, Llc	Method of treating breast cancer using a combination of vitamin D analogues and other agents
KR20070088695A (ko) *	2005-10-05	2007-08-29	시코르, 인크.	풀베스트란트 이성질체의 분리 방법
US20080064669A1 (en) *	2006-08-29	2008-03-13	Rakefet Cohen	Stable pharmacologically active compositions including vitamin D-containing and corticosteroid compounds with low pH compatibility
WO2009108388A2 (en) *	2008-02-28	2009-09-03	University Of Tennessee Research Foundation	Enzymatic production or chemical synthesis and uses for 5,7-dienes and uvb conversion products thereof
JPWO2010053165A1 (ja)	2008-11-04	2012-04-05	帝人ファーマ株式会社	ビタミンｄ３ラクタム誘導体
CA2981549A1 (en) *	2009-01-27	2010-08-05	Berg Llc	Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
CN106265695B (zh)	2009-08-14	2021-05-07	博格有限责任公司	用于治疗脱发的维生素d3及其类似物
US9834512B2 (en)	2011-06-03	2017-12-05	Wisconsin Alumni Research Foundation	(22E)-2-methylene-26,27-cyclo-22-dehydro-1α-hydroxy-19-norvitamin D3 derivatives
US10479764B2 (en)	2011-06-28	2019-11-19	Wisconsin Alumni Research Foundation	2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs
CN112156097A (zh)	2013-05-29	2021-01-01	博格有限责任公司	使用维生素d预防或减轻化疗诱发的脱发
WO2022078877A1 (en)	2020-10-12	2022-04-21	Universite De Strasbourg	A calcium normalizer targeting the vitamin d receptor and therapeutic uses thereof
GB202016614D0 (en)	2020-10-20	2020-12-02	King S College London	Compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5182396A (en) *	1991-03-29	1993-01-26	Nisshin Flour Milling Co., Ltd.	1-hydroxyvitamin d derivatives
IL107185A (en) *	1992-10-06	1998-02-22	Schering Ag	Vitamin d, 25-carboxylic acid derivatives and pharmaceutical compositions containing the same

1996
- 1996-04-30 ES ES96915001T patent/ES2144239T3/es not_active Expired - Lifetime
- 1996-04-30 JP JP9502535A patent/JPH11507649A/ja not_active Ceased
- 1996-04-30 EP EP96915001A patent/EP0832063B1/de not_active Expired - Lifetime
- 1996-04-30 CA CA002224440A patent/CA2224440A1/en not_active Abandoned
- 1996-04-30 AT AT96915001T patent/ATE189888T1/de not_active IP Right Cessation
- 1996-04-30 NZ NZ307549A patent/NZ307549A/xx unknown
- 1996-04-30 DK DK96915001T patent/DK0832063T3/da active
- 1996-04-30 DE DE59604498T patent/DE59604498D1/de not_active Expired - Fee Related
- 1996-04-30 PT PT96915001T patent/PT832063E/pt unknown
- 1996-04-30 US US08/981,819 patent/US6372731B1/en not_active Expired - Fee Related
- 1996-04-30 WO PCT/EP1996/001788 patent/WO1997000242A1/de not_active Ceased
- 1996-04-30 AU AU56930/96A patent/AU707942B2/en not_active Ceased
- 1996-04-30 HU HU9801059A patent/HUP9801059A3/hu unknown
- 1996-04-30 CZ CZ19974031A patent/CZ291915B6/cs not_active IP Right Cessation
- 1996-05-22 IL IL11836696A patent/IL118366A/en not_active IP Right Cessation
- 1996-05-23 TW TW085106144A patent/TW351714B/zh active
- 1996-06-14 ZA ZA965098A patent/ZA965098B/xx unknown
1997
- 1997-12-12 NO NO19975852A patent/NO317059B1/no unknown
2000
- 2000-05-19 GR GR20000401148T patent/GR3033459T3/el not_active IP Right Cessation
- 2000-12-18 US US09/738,286 patent/US6376480B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL118366A0 (en)	1996-09-12
AU707942B2 (en)	1999-07-22
JPH11507649A (ja)	1999-07-06
TW351714B (en)	1999-02-01
US6376480B1 (en)	2002-04-23
HUP9801059A2 (hu)	1998-08-28
CA2224440A1 (en)	1997-01-03
HUP9801059A3 (en)	1999-05-28
IL118366A (en)	2004-12-15
ES2144239T3 (es)	2000-06-01
GR3033459T3 (en)	2000-09-29
NO975852D0 (no)	1997-12-12
NZ307549A (en)	1999-11-29
DE59604498D1 (de)	2000-03-30
US6372731B1 (en)	2002-04-16
ZA965098B (en)	1997-01-22
DK0832063T3 (da)	2000-06-13
NO975852L (no)	1998-02-16
PT832063E (pt)	2000-06-30
CZ291915B6 (cs)	2003-06-18
EP0832063A1 (de)	1998-04-01
ATE189888T1 (de)	2000-03-15
CZ403197A3 (cs)	1998-07-15
WO1997000242A1 (de)	1997-01-03
EP0832063B1 (de)	2000-02-23
AU5693096A (en)	1997-01-15

Publication	Publication Date	Title
NO317059B1 (no)	2004-08-02	Nye vitamin D-derivater med C-25-substituenter, fremgangsmate for fremstilling av disse, mellomprodukter og anvendelse av vitamin D-derivatene ved fremstilling av legemidler
EP0663902B1 (de)	1998-03-11	25-carbonsäure-derivate in der vitamin d-reihe, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
JP2002505668A (ja)	2002-02-19	環状エーテルビタミンＤ３化合物、１α（ＯＨ）３−エピ−ビタミンＤ３化合物及びそれらの使用法
AU690564B2 (en)	1998-04-30	Novel vitamin D analogues
KR100399661B1 (ko)	2004-04-30	비타민d및아마이드유도체
US5250523A (en)	1993-10-05	Side chain unsaturated 1α-hydroxyvitanim D homologs
US7241748B2 (en)	2007-07-10	17,20(Z)-dehydro vitamin D analogs and their uses
US20060293291A1 (en)	2006-12-28	2-Propylidene-19-nor-vitamin d compounds
DE69910031T2 (de)	2004-04-29	Verfahren zur herstellung von hydroxy-25-ene vitamin d verbindungen
EP1025082B1 (de)	2003-05-02	Neue vitamin d-derivate mit cyclopropylringen in den seitenketten, verfahren und zwischenprodukte zu ihrer herstellung sowie ihre verwendung zur herstellung von arzneimitteln
CA2562535C (en)	2012-07-10	2-alkylidene-18,19-dinor-vitamin d compounds
US5354744A (en)	1994-10-11	Side chain unsaturated 1 alpha-hydroxyvitamin D analogs
KR20050055784A (ko)	2005-06-13	비타민 디 유사체, 이 유사체를 포함하는 조성물 및 이들의용도
AU2005309747A1 (en)	2006-06-01	2-methylene-18,19-dinor-1alpha-hydroxy-homopregnacalciferol and its uses
MX2007011919A (es)	2007-11-22	2-metilen-19-nor-(23s)-25-deshidro-1a-hidroxivitamina d3-26,23-lactona y 2-metilen19-nor-(23r)-25-deshidro-1a- hidroxivitamina d3-26,23-lactona.